Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03428919
Other study ID # CS/MD/17/12
Secondary ID CS/AS/17/10
Status Completed
Phase N/A
First received
Last updated
Start date March 16, 2018
Est. completion date August 12, 2020

Study information

Verified date October 2020
Source M? Ð?c Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Conventionally, ICSI was initially developed and has been shown to be an effective treatment for male factor infertility. It is increasingly being used for patients without a male factor diagnosis, despite the lack of clinical evidence to support its use. Moreover, ICSI is an invasive and expensive procedure. This multi-center, randomized, controlled, parallel-group trial will be conducted to compare the effectiveness of ICSI versus conventional IVF in infertile couples scheduled for IVF treatment, in whom the male partner has normal sperm.


Description:

All patients undergoing IVF/ICSI will be treated with a GnRH antagonist protocol. Recombinant FSH (Puregon, MSD) will be given on day 2 or day 3 of menstrual cycle for 5 days. The starting dose is individualized for each patient based on the following criteria: AMH <0.7 ng/mL, dose 300 IU/day; AMH 0.7-2.1 ng/mL, dose 200 IU/day; AMH >2.1 ng/mL, dose 150 IU/day. After that, investigators can titrate the dose based on their clinical judgment. Follicular development will be monitored by ultrasound scanning and measurement of estradiol and progesterone levels, starting on day 5 of stimulation. Scanning and hormonal measurement will be repeated every 2 to 3 days, depending on the size of follicles. An antagonist is routinely used on day 5 until the day of triggering. Criteria for triggering, by hCG (Ovitrelle 250 mg, Merck, Germany) will be the presence of at least three leading follicles of 17 mm. In women with excessive follicular response (≥15 follicles ≥12 mm), 0,2 mg Triptorelin (Diphereline, Ipsen Beaufour, France) will be used when there are at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.

Randomization and allocation of participants to study groups will be performed on the day of egg pick up, after having obtained the semen from the husband. Eligible participants that have provided informed consent will be randomised to either ICSI or conventional IVF.

In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.

In conventional IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.

In both groups, fertilization check will be performed under inverted microscope at period of 16-18 hours after insemination. On day 3, embryo evaluation will be performed at fixed time point 66±2 hours after fertilization, using the Istanbul consensus. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen. Luteal-phase support will be done with estradiol (Valiera 2mg) 8mg/day and vaginal progesterone 800mg/day (Cyclogest 400mg) until 7th week of gestation.

If there are contra-indications for fresh embryo transfer, a freeze-all strategy will be applied, using Cryotech technique. Indications for freeze-all include: risk of ovarian hyperstimulation syndrome (OHSS), premature progesterone rise (≥1.5 ng/ml), thin endometrium (<7 mm), fluid in cavity on day of embryo transfer, endometrial polyp, hydrosalpinx that have not removed before oocyte retrieval.

In the next cycle, endometrium will be prepared by using estradiol (Valiera 2 mg, 8 mg/day) orally, starting from day 2-3 of menstrual cycle. When the endometrium thickness reaches 8 mm or more, patients will start using progesterone vaginally (Cyclogest 400 mg, 800 mg/day). Embryo transfer will be performed 3 days after using progesterone. On the day of embryo transfer, embryos will be thawed. In the frozen/thawed cycle, the best embryos will be utilized first, as in fresh transfer. Two hours after thawing, a maximum of 2 surviving embryos will be transferred into the uterus under ultrasound guidance. Luteal phase support will be provided with estradiol (Valiera 2mg) 8mg/day and vaginal progesterone 800 mg/day (Cyclogest 400 mg) until the seventh week of gestation.

In both groups, clinicians who perform embryo transfer, either fresh or frozen cycles, will be blinded to the intervention.

A serum hCG will be measured 2 weeks after embryo transferred, and if positive, an ultrasound scan of the uterus will be performed at gestational weeks 7 and 12. At 11 - 12 weeks of gestation, participants will be referred to the Outpatient clininc, O&G Department, My Duc hospital or An Sinh hospital for prenatal care until giving birth.


Recruitment information / eligibility

Status Completed
Enrollment 1064
Est. completion date August 12, 2020
Est. primary completion date August 1, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Having = 2 IVF/ICSI cycles

- Total sperm count and motility are normal (WHO, 2010)

- Antagonist protocol

- Agree to have = 2 embryos transferred

- Not participating in another IVF study at the same time

Exclusion Criteria:

- In-vitro maturation (IVM) cycles

- Using frozen semen

- Poor fertilization in previous cycle (= 25%)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
ICSI
In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
IVF
In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.

Locations

Country Name City State
Vietnam Dang Q Vinh Hochiminh city

Sponsors (2)

Lead Sponsor Collaborator
M? Ð?c Hospital An Sinh Hospital

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ongoing pregnancy resulting in live birth after the first embryo transfer of the started treatment cycle. Live birth is defined as the birth of at least one newborn after 24 weeks' gestation that exhibits any sign of life (twin will be a single count).
For the timing of this occur, ongoing pregnancy will be used, conditional on the fact that this ongoing pregnancy results in live birth.
At 12 weeks of gestation
Secondary Fertilization rate per oocyte inseminated/injected Fertilization is defined as the appearance of 2 PN At 16-18 hours after injected or 17-19 hours after inseminated
Secondary Fertilization rate per oocyte retrieved Fertilization is defined as the appearance of 2 PN At 16-18 hours after injected or 17-19 hours after inseminated
Secondary Abnormal fertilization rate Abnormal fertilization is defined as the appearance of 1PN or =3 PN At 16-18 hours after injected or 17-19 hours after inseminated
Secondary Total fertilization failure rate Total fertilization is defined as the absence of any zygotes with 2PN At 16-18 hours after injected or 17-19 hours after inseminated
Secondary Number of embryos on day 3 Number of embryos on day 3 3 days after oocytes pick-up day in IVF/ICSI
Secondary Number of good quality embryo on day 3 Numbers of embryos on day 3 with good quality 3 days after oocytes pick-up day in IVF/ICSI
Secondary Number of embryo freezing on day 3 Number of embryos freezing on day 3 3 days after oocytes pick-up day in IVF/ICSI
Secondary Positive pregnancy test Positive pregnancy test is defined as a serum human chorionic gonadotropin level greater than 25 mIU/mL after the completion of the first transfer 14 days after embryo transfer
Secondary Clinical pregnancy Clinical pregnancy is defined as the presence of at least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity, after the completion of the first transfer At 7 weeks' gestation
Secondary Implantation rate Implantation rate is defined as the number of gestational sacs per number of embryos transferred after the completion of the first transfer At 3 weeks after embryo transferred
Secondary Ongoing pregnancy Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after the completion of the first transfer At 12 weeks' gestation
Secondary Cumulative ongoing pregnancy Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after transfer of all embryos from the started treatment cycle. At 12 weeks' gestation at 12 months after randomization. After 12 months, most patients doing IVF have finished all their frozen embryos; therefore, we consider this time point for analyzing the cumulative ongoing pregnancy rate.
Secondary Ongoing pregnancy resulting in live birth obtained from all embryos from the first started treatment cycle Live birth is defined as the birth of at least one newborn after 24 weeks' gestation that exhibits any sign of life (twin will be a single count). 12 weeks of gestation at 12 months after randomization
Secondary Time from randomization to ongoing pregnancy Time from randomization to ongoing pregnancy after the completion of the first transfer 12 weeks of gestation after the completion of first transfer
Secondary Ovarian hyperstimulation syndrome (OHSS) Symptoms of OHSS At 10 days after hCG injection and 14 days after embryo transfer
Secondary Ectopic pregnancy A pregnancy in which implantation takes place outside the uterine cavity after completion of the first transfer At 12 weeks of gestation after the completion of the first transfer
Secondary Ectopic pregnancy A pregnancy in which implantation takes place outside the uterine cavity after transfer of all embryos from the started treatment cycle. At 12 weeks of gestation at 12 months after randomization.
Secondary Miscarriage The loss of a clinical pregnancy at 24 weeks of gestation after the completion of the first transfer At 24 weeks of gestation after the completion of the first transfer
Secondary Miscarriage The loss of a clinical pregnancy at 24 weeks of gestation after the completion transfer of all embryos from the started treatment cycle At 24 weeks of gestation at 12 months after the randomization.
Secondary Multiple pregnancy Multiple pregnancy is explained as two or more gestational sacs or positive heart beats by transvaginal sonography, after the completion of the first transfer 7 weeks' gestation after the completion of the first transfer
Secondary Multiple pregnancy Multiple pregnancy is explained as two or more gestational sacs or positive heart beats by transvaginal sonography, after the completion transfer of all embryos from the started treatment cycle 7 weeks' gestation at 12 months after randomization
Secondary Multiple delivery Multiple delivery is defined as birth of more than one baby beyond 24 weeks, after the completion of the first transfer At birth, after the completion of the first transfer
Secondary Multiple delivery Multiple delivery is defined as birth of more than one baby beyond 24 weeks, after the completion transfer of all embryos from the started treatment cycle At birth at 12 months after randomization
Secondary Gestational diabetes mellitus Development of diabetes during pregnancy At 24 weeks of gestation after the completion of the first transfer
Secondary Gestational diabetes mellitus Development of diabetes during pregnancy At 24 weeks of gestation at 12 months after randomization
Secondary Hypertensive disorders of pregnancy Hypertensive disorders of pregnancy will include pregnancy induced hypertension (PIH); pre-eclampsia (PET) and eclampsia) From 20 weeks of gestation up to at birth after the completion of the first transfer
Secondary Hypertensive disorders of pregnancy Hypertensive disorders of pregnancy will include pregnancy induced hypertension (PIH); pre-eclampsia (PET) and eclampsia) From 20 weeks of gestation up to at birth at 12 months after randomization
Secondary Antepartum haemorrhage Including placenta previa, placenta accreta and unexplained From 20 weeks of gestation up to at birth, after the completion of the first transfer
Secondary Antepartum haemorrhage Including placenta previa, placenta accreta and unexplained From 20 weeks of gestation up to at birth, at 12 months after randomization
Secondary Gestational age at delivery Gestational age at delivery At birth, after the completion of the first transfer
Secondary Gestational age at delivery Gestational age at delivery At birth, at 12 months after randomization
Secondary Preterm delivery Preterm delivery is defined as any delivery at <24, <28, <32, <37 completed weeks' gestation At birth, after the completion of the first transfer
Secondary Preterm delivery Preterm delivery is defined as any delivery at <24, <28, <32, <37 completed weeks' gestation At birth, at 12 months after randomization
Secondary Spontaneous preterm birth Spontaneous preterm birth is defined as delivery spontaneously at <24, <28, <32, <37 completed weeks At birth, after the completion of the first transfer
Secondary Spontaneous preterm birth Spontaneous preterm birth is defined as delivery spontaneously at <24, <28, <32, <37 completed weeks At birth, at 12 months after randomization
Secondary Iatrogenic preterm birth Iatrogenic preterm birth is defined as delivery non-spontaneously at <24, <28, <32, <37 completed weeks At birth, after the completion of the first transfer
Secondary Iatrogenic preterm birth Iatrogenic preterm birth is defined as delivery non-spontaneously at <24, <28, <32, <37 completed weeks At birth, at 12 months after randomization
Secondary Birth weight Weight of newborn At birth, after the completion of the first transfer
Secondary Birth weight Weight of newborn At birth, at 12 months after randomization
Secondary Low birth weight Low birth weight is defined as <2500 gm At birth, after the completion of the first transfer
Secondary Low birth weight Low birth weight is defined as <2500 gm At birth, at 12 months after randomization
Secondary Very low birth weight Very low birth weight is defined as <1500 gm At birth, after the completion of the first transfer
Secondary Very low birth weight Very low birth weight is defined as <1500 gm At birth, at 12 months after randomization
Secondary High birth weight High birth weight is defined as >4000 gm At birth, after the completion of the first transfer
Secondary High birth weight High birth weight is defined as >4000 gm At birth, at 12 months after randomization
Secondary Very high birth weight Very high birth weight is defined as >4500 gm At birth, after the completion of the first transfer
Secondary Very high birth weight Very high birth weight is defined as >4500 gm At birth, at 12 months after randomization
Secondary Large for gestational age Large for gestational age is defined as birth weight >90th percentile At birth, after the completion of the first transfer
Secondary Large for gestational age Large for gestational age is defined as birth weight >90th percentile At birth, at 12 months after randomization
Secondary Small for gestational age Small for gestational age is defined as birth weight <10th percentile At birth, after the completion of the first transfer
Secondary Small for gestational age Small for gestational age is defined as birth weight <10th percentile At birth, at 12 months after randomization
Secondary Congenital anomaly diagnosed at birth Any congenital anomaly will be included At birth, after the completion of the first transfer
Secondary Congenital anomaly diagnosed at birth Any congenital anomaly will be included At birth, at 12 months after randomization
Secondary Admission to NICU The admittance of the newborn to NICU 7 days after delivery after the completion of the first transfer
Secondary Admission to NICU The admittance of the newborn to NICU 7 days after delivery, at 12 months after randomization
Secondary Genetic and epigenetic analysis of newborn Maternal whole blood; newborn's materials including cord blood, neonatal buccal smear, and placental tissue will be collected. Data will be collected for a supplementary analysis and will be reported in a separated paper. 1 day (Prior to the initiation of IVF/IVM) and 1 day ( at the time of delivery)
Secondary Cost-effectiveness Including direct and indirect costs; costs related to complications treatment. Cost data will be collected for a supplementary analysis and will be reported in a separated paper. Two year after randomization
See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A